A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

Phase 3 Terminated 86 enrolled Pfizer Medivation, Inc. · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine.

Timeline

Start: 2009-09
Primary completion: 2010-08
Completion: 2010-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Latrepirdine	Small molecule	20 mg	Oral

A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

Summary

Timeline

Drugs

Indications